司美格鲁肽对2型糖尿病和/或肥胖者肝酶及炎症标志物的影响
该研究分析了两项临床试验数据:一项104周2型糖尿病心血管结局试验(司美格鲁肽0.5或1.0 mg/周)和一项52周体重管理试验(司美格鲁肽0.05-0.4 mg/天)。在基线ALT升高的受试者中,司美格鲁肽显著降低ALT和hsCRP,但校正体重变化后差异无统计学意义。
要点
- 体重管理试验中基线ALT升高者占52%(499/957),司美格鲁肽治疗使ALT降低6%-21%,hsCRP降低25%-43%(vs 安慰剂)。
- 心血管结局试验中基线ALT升高者占41%(1325/3268),1.0 mg/周组ALT降低9%(vs 安慰剂,P=0.0024),0.5 mg/周组无显著降低。
- 校正体重变化后,ALT和hsCRP的治疗差异均无统计学意义。
核心结论
- 在肥胖和/或2型糖尿病受试者的临床试验中,司美格鲁肽显著降低ALT和hsCRP。
研究设计与样本
- 分析两项试验数据:104周2型糖尿病心血管结局试验(司美格鲁肽0.5或1.0 mg/周)和52周体重管理试验(司美格鲁肽0.05-0.4 mg/天)。
- 采用混合模型重复测量估计ALT(两项试验)和hsCRP(仅体重管理试验)相对于安慰剂的治疗比值,分析时校正或不校正体重变化。
主要发现
- 体重管理试验中基线ALT升高(男>30 IU/L;女>19 IU/L)者占52%(499/957)。
- 在体重管理试验基线ALT升高组中,治疗结束时ALT降低6%-21%(剂量≥0.2 mg/天时P<0.05),hsCRP降低25%-43%(vs 安慰剂,0.2和0.4 mg/天时P<0.05)。
- 体重管理试验中基线ALT升高者恢复正常比例:司美格鲁肽组25%-46%,安慰剂组18%。
- 心血管结局试验中基线ALT升高者占41%(1325/3268);该组中0.5 mg/周治疗结束时ALT无显著降低,1.0 mg/周组ALT降低9%(vs 安慰剂,P=0.0024)。
- 校正体重变化后,ALT和hsCRP变化的治疗比值均无统计学意义。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Obesity and type 2 diabetes are drivers of non-alcoholic fatty liver disease (NAFLD). Glucagon-like peptide-1 analogues effectively treat obesity and type 2 diabetes and may offer potential for NAFLD treatment. AIM: To evaluate the effect of the glucagon-like peptide-1 analogue, semaglutide, on alanine aminotransferase (ALT) and high-sensitivity C-reactive protein (hsCRP) in subjects at risk of NAFLD. METHODS: Data from a 104-week cardiovascular outcomes trial in type 2 diabetes (semaglutide 0.5 or 1.0 mg/week) and a 52-week weight management trial (semaglutide 0.05-0.4 mg/day) were analysed. Treatment ratios vs placebo were estimated for ALT (both trials) and hsCRP (weight management trial only) using a mixed model for repeated measurements, with or without adjustment for change in body weight. RESULTS: Elevated baseline ALT (men >30 IU/L; women >19 IU/L) was present in 52% (499/957) of weight management trial subjects. In this group with elevated ALT, end-of-treatment ALT reductions were 6%-21% (P<0.05 for doses≥0.2 mg/day) and hsCRP reductions 25%-43% vs placebo (P < 0.05 for 0.2 and 0.4 mg/day). Normalisation of elevated baseline ALT occurred in 25%-46% of weight management trial subjects, vs 18% on placebo. Elevated baseline ALT was present in 41% (1325/3268) of cardiovascular outcomes trial subjects. In this group with elevated ALT, no significant ALT reduction was noted at end-of-treatment for 0.5 mg/week, while a 9% reduction vs placebo was seen for 1.0 mg/week (P = 0.0024). Treatment ratios for changes in ALT and hsCRP were not statistically significant after adjustment for weight change. CONCLUSIONS: Semaglutide significantly reduced ALT and hsCRP in clinical trials in subjects with obesity and/or type 2 diabetes.
引用
- Newsome P, Francque S, Harrison S, et al. Effect of semaglutide on liver enzymes and markers of inflammation in subjects with type 2 diabetes and/or obesity. Aliment Pharmacol Ther. 2019. PMID: 31246368. doi:10.1111/apt.15316
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。